| Zacks Company Profile for Xenetic Biosciences, Inc. (XBIO : NSDQ) |
|
|
| |
| • Company Description |
| Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Number of Employees: 2 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $3.83 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 186,204 shares |
| Shares Outstanding: 1.54 (millions) |
| Market Capitalization: $5.91 (millions) |
| Beta: 2.34 |
| 52 Week High: $5.27 |
| 52 Week Low: $2.20 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
18.26% |
13.84% |
| 12 Week |
57.59% |
32.55% |
| Year To Date |
-3.96% |
-10.06% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
James Parslow - Interim Chief Executive Officer and Chief Financia
Grigory Borisenko - Director
Firdaus Jal Dastoor - Director
Dmitry Genkin - Director
Roger Kornberg - Director
|
|
Peer Information
Xenetic Biosciences, Inc. (GSAC)
Xenetic Biosciences, Inc. (CASI)
Xenetic Biosciences, Inc. (ALCD.)
Xenetic Biosciences, Inc. (OMNN)
Xenetic Biosciences, Inc. (CGPI.)
Xenetic Biosciences, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 984015602
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 1.54
Most Recent Split Date: 5.00 (0.10:1)
Beta: 2.34
Market Capitalization: $5.91 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.65 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.56 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
